Clinical trials in China are evolving rapidly.

Western world pharma and biotech companies are showing great interest in performing clinical studies in China, and Chinese investigators are waiting to take part in international M/C studies.

Because of the abundance of patients in China, all therapeutic indications are represented in high numbers. In addition, drug naive patients are possible for study purposes in significant numbers.

The GCP standard of investigators is very high. China has since several years a national organisation for training and certification of MDs in Good Clinical Practice. The time for regulatory approval of clinical trials by national and regional authorities has decreased significant, and is comparable to EU and US standards.

Major hospitals are technically well equipped with experienced MDs and structured management.

In summary, the medical society in China is well prepared for high level participation in international clinical research.